Cabergoline is a long acting ergot derived dopamine agonist with FDA approval for hyperprolactinaemia treatment and one of the most extensively documented clinical literature bases of any prolactin regulating compound. This generic brand formulation delivers 0.5mg per tablet in a 4 count format, a compact low supply presentation distinct from CSD’s Pfizer Dostinex 0.5mg 8 tablet pharmaceutical format, providing the lowest procurement commitment in CSD’s Cabergoline range and suited to researchers initiating Cabergoline protocols, conducting single cycle evaluation before committing to the Pfizer 8 tablet pharmaceutical presentation, or research designs where a defined 4 dose administration sequence is the experimental endpoint.
The 4 tablet format is pharmacokinetically practical for Cabergoline specifically. Cabergoline’s exceptionally long half-life of approximately 63 to 68 hours enables twice weekly administration in documented clinical research protocols. Meaning four tablets at twice weekly dosing supports a two week research observation window from a single pack procurement. For initial dose response characterization studies, short duration comparative dopamine agonist research, or protocols examining the acute prolactin suppression response to Cabergoline administration across a defined two week timeline, the 4 tablet supply provides a precisely matched compound volume without excess beyond the protocol’s defined endpoint.
Cabergoline’s core pharmacological profile remains consistent with CSD’s Pfizer Dostinex listing; selective D2 receptor agonism at pituitary lactotroph cells producing sustained prolactin suppression through the same inhibitory dopamine signaling pathway as endogenous dopamine, long acting receptor engagement enabling twice weekly administration, and a more pituitary targeted D2 receptor selectivity profile compared to Pramipexole’s higher D3 limbic receptor affinity. The generic brand sourcing and reduced 4 tablet format represent the primary differentiating variables from the Pfizer Dostinex presentation, base compound, concentration, mechanism, and pharmacological activity remaining identical across both listings.
Every batch of CSD’s Cabergoline is third party lab tested for concentration accuracy and purity before being made available, with COA documentation available on request. Canada Steroid Depot stocks Cabergoline across two presentations: this generic brand 4 tablet format and the Pfizer Dostinex 8 tablet pharmaceutical format. Alongside Pramipexole for complete dopamine agonist prolactin regulation research coverage from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside Pramipexole in comparative dopamine agonist and prolactin regulation studies. Browse CSD’s full hormone research range for complete sourcing.
